Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
Philip Weir, David Donaldson, Mary Frances McMullin, Lisa Crawford
Abstract
Despite significant improvements in treatment strategies over the past couple of decades, multiple myeloma (MM) remains an incurable disease due to the development of drug resistance. Metabolic reprogramming is a key feature of cancer cells, including MM, and acts to fuel increased proliferation, create a permissive tumour microenvironment, and promote drug resistance. This review presents an overview of the key metabolic adaptations that occur in MM pathogenesis and in the development of resistance to proteasome inhibitors, the backbone of current MM therapy, and considers the potential for therapeutic targeting of key metabolic pathways to improve outcomes.
Topics & Concepts
Multiple myelomaProteasomeCancer researchDrug resistanceProteasome inhibitorCarcinogenesisReprogrammingBortezomibPathogenesisDrug developmentCancerMedicinePermissiveBioinformaticsDrugBiologyPharmacologyImmunologyCell biologyInternal medicineCellBiochemistryGeneticsMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsHistone Deacetylase Inhibitors Research